The Roivant-Sumitomo Deal: $3 Billion, 5 Companies, $550 Million in Loans and an Option on 6 More...

In September, Roivant Sciences, Vivek Ramaswamy’s umbrella biotech company, agreed to sell ownership of five of its Vant companies to Japan’s Sumitomo Dainippon Pharma for $3 billion. Sumitomo Dainippon also was buying an equity stake of more than 10% of Roivant shares.

The companies have released more details of the deal, which includes an option on six more Vant companies until 2024.